February 2020
The GreenFund – A new study has found that medicinal cannabis may be able to reduce the intensity of chronic pain in patients by as much as 30%. A new study conducted by Southern Cannabis Holdings (SCH) has found that medicinal cannabis may be a highly effective treatment option for patients suffering from chronic pain....
Read More
Applied cannabis research - mgc pharma
STOCKHEAD MGC (ASX:MXC) will conduct a head-to-head clinical study on severe intractable epilepsy in collaboration with Cannabis Access Clinics and Epilepsy Action Australia, a direct comparison assessing the efficacy of low-THC to 100 per cent CBD products when treating severe intractable epilepsy. Read more : Ethics body approves another clinical trial using MGC Pharma’s epilepsy drug
Read More
The study will be conducted in collaboration with CA Clinics and is one of the first of its kind globally. A new study aimed at assessing the efficacy of THC-based medications for sufferers of cachexia was launched this week by Applied Cannabis Research (ACR), a division of Southern Cannabis Holdings (SCH). Read more: Applied Cannabis...
Read More